Contemporary use of anticoagulation in the cardiac catheterization laboratory: a review.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
20
8
2021
medline:
8
4
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
Anticoagulation during percutaneous coronary interventions has a rich history that has been shaped by several key clinical trials. The correct choice of anticoagulation during interventions can maximize patient outcomes and ensure a safe procedure. However, in some specific situations, anticoagulation may not be required at all. In this review article, we review the significant clinical trials and current guidelines regarding the use of anticoagulation in the catheterization laboratory and discuss the unique pharmacological aspects of the most commonly used agents, with an emphasis on the specific pharmacokinetic parameters that dictate how these agents are used and monitored. Finally, we discussed the future directions in anticoagulation therapy in coronary artery disease. This review serves as a robust synopsis of the clinical data for practicing clinicians and fellows in training.
Identifiants
pubmed: 34411013
doi: 10.1097/MCA.0000000000001095
pii: 00019501-202205000-00009
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-232Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
van der Meer JY, Kellenbach E, van den Bos LJ. From farm to pharma: an overview of industrial heparin manufacturing methods. Molecules 2017; 22:E1025.
Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359:2674–2684.
Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001; 21:1094–1096.
Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69:570–577.
Yang L, Manithody C, Rezaie AR. Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. Blood 2004; 104:1753–1759.
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S–94S.
Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41:15–31.
DeLoughery T. Heparins and heparin-induced thrombocytopenia. DeLoughery, T, editor. In: Hemostasis and Thrombosis. 4th ed. Switzerland: Springer Nature; 2019. pp. 145–150.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44–122.
Doherty TM, Shavelle RM, French WJ. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2005; 65:330–337.
Thomas S, Makris M. The reversal of anticoagulation in clinical practice . Clin Med (Lond) 2018; 18:314–319.
Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P T 2010; 35:95–105.
Haines ST, Racine E, Aeolla M. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. In: Pharmacotherapy: a pathophysiologic approach. 6th ed. McGraw- Hill; 2005. pp. 337–373.
Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism [published correction appears in J Thromb Thrombolysis. 2016 Aug;42(2):296-311]. J Thromb Thrombolysis 2016; 41:15–31.
Ramana RK, Lewis BE. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin. Vasc Health Risk Manag 2008; 4:493–505.
Sheikh-Taha M, Ghosn S. Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. J Pharm Pract 2012; 25:537–540.
Samama MM, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109:1–11.
Fondaparinux (Arixtra®) product package insert. GlaxoSmithKline; 2008.
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al.; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006–1017.
Montalescot G, Cohen M, Salette G, Desmet WJ, Macaya C, Aylward PE, et al.; STEEPLE Investigators. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur Heart J 2008; 29:462–471.
Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al.; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853–863.
Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, et al.; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688–696.
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, et al.; ASPIRE Investigators. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111:1390–1397.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354:1464–1476.
Denardo SJ, Davis KE, Tcheng JE. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 2005; 149:138–144.
Valencia R, Price MJ, Sawhney N, Lee SS, Wong GB, Gollapudi RR, et al. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial). Am J Cardiol 2007; 100:1099–1102.
Stabile E, Nammas W, Salemme L, Sorropago G, Cioppa A, Tesorio T, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008; 52:1293–1298.
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40:87–165.
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355:1936–1942.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64:e139–e228.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; 42:1289–1367.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al.; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.
Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, et al.; ‘A to Z’ Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292:55–64.
O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:e78–e140.
Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C Jr, et al. Activated clotting time to guide heparin dosing in non-ST-segment-elevation acute coronary syndrome patients undergoing percutaneous coronary intervention and treated with IIb/IIIa inhibitors: impact on ischemic and bleeding outcomes: insights from the TAO trial. Circ Cardiovasc Interv 2018; 11:e006084.
Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al.; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203–2216.
Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, et al. Bivalirudin versus heparin monotherapy in myocardial infarction. N Engl J Med 2017; 377:1132–1142.
Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA 2010; 304:1339–1349.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39:119–177.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al.; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519–1530.
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al.; ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378:693–703.
Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344:e553.
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al.; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374:1149–1159.
Steg PG, van ‘t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al.; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369:2207–2217.
Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, et al.; MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373:997–1009.
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al.; HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384:1849–1858.
Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al.; BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015; 313:1336–1346.
Kheiri B, Rao SV, Osman M, Simpson TF, Barbarawi M, Zayed Y, et al. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. Catheter Cardiovasc Interv 2020; 96:1240–1248.
Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873–2891.
Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, et al.; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377:1409–1420.
Nørgaard BL, Hjort J, Gaur S, Hansson N, Bøtker HE, Leipsic J, et al. Clinical Use of coronary CTA-derived FFR for decision-making in stable CAD. JACC Cardiovasc Imaging 2017; 10:541–550.
Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, et al. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost 2015; 114:258–267.